Bimokalner

Bimokalner

SCHEMBL29418836

O=C(NCc1cccc(S(F)(F)(F)(F)F)c1)[C@@H]1C[C@H]2CC[C@@H]1C2

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.67
▸ POLB P06746 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ KCNQ3 O43525 1/20 0.40
▸ KCNQ2 O43526 1/20 0.40
▸ KCNQ4 P56696 1/20 0.40
▸ KCNQ5 Q9NR82 1/20 0.40
▸ ACKR3 P25106 1/20 0.40
▸ MC4R P32245 1/20 0.39
▸ MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bimokalner SCHEMBL26655096 1.00 HPGD (0.67) HPGDPOLBHSD17B10L3MBTL1KDM4E
Bimokalner SCHEMBL20477551 1.00 HPGD (0.67) HPGDPOLBHSD17B10L3MBTL1KDM4E
Bimokalner SCHEMBL22017037 1.00 HPGD (0.67) HPGDPOLBHSD17B10L3MBTL1KDM4E
Bimokalner SCHEMBL20477545 1.00 HPGD (0.67) HPGDPOLBHSD17B10L3MBTL1KDM4E
Bimokalner SCHEMBL26655211 1.00 HPGD (0.67) HPGDPOLBHSD17B10L3MBTL1KDM4E
Bimokalner SCHEMBL29418602 1.00 HPGD (0.67) HPGDPOLBHSD17B10L3MBTL1KDM4E
SCHEMBL20477558 0.81 HPGD (0.67) HPGDPOLBL3MBTL1KDM4EHTT
SCHEMBL21541951 0.81 HPGD (0.67) HPGDPOLBL3MBTL1KDM4EHTT
SCHEMBL29418795 0.81 HPGD (0.67) HPGDPOLBL3MBTL1KDM4EHTT
SCHEMBL29418612 0.81 HPGD (0.67) HPGDPOLBL3MBTL1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725937-A1 PROCESS FOR THE SYNTHESIS OF BICYCLIC CARBOXAMIDE COMPOUNDS Acousia Therapeutics GmbH (DE) 2026-04-15 — — EP claimed
CN-110312710-B Compounds useful as potassium channel openers 阿库西亚医疗有限责任公司 2022-02-15 — — CN claimed
US-20260083669-A1 AQUEOUS GEL COMPOSITION ACOUSIA THERAPEUTICS GMBH (DE) 2026-03-26 — — US disclosed
CN-114105942-B Compounds useful as potassium channel openers 阿库西亚医疗有限责任公司 2024-07-12 — — CN disclosed
EP-4362916-A1 AQUEOUS GEL COMPOSITION Acousia Therapeutics GmbH (DE) 2024-05-08 — — EP disclosed
CN-117881393-A Aqueous gel composition 阿库西亚医疗有限责任公司 2024-04-12 — — CN disclosed
WO-2023222795-A1 AQUEOUS GEL COMPOSITION ACOUSIA THERAPEUTICS GMBH (DE) 2023-11-23 — — WO disclosed
CN-116600787-A Nonaqueous gel composition 阿库西亚医疗有限责任公司 2023-08-15 — — CN disclosed
CN-110312710-B Compounds useful as potassium channel openers 阿库西亚医疗有限责任公司 2022-02-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083669-A1 AQUEOUS GEL COMPOSITION CFTR, AQP3, SLC26A4 HPGD 1470/4885POLB 1438/4885HSD17B10 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback